Department of Physiology, Faculty of Medicine, Süleyman Demirel University, 32260, Isparta, Turkey.
Mol Cell Biochem. 2009 Nov;331(1-2):43-8. doi: 10.1007/s11010-009-0143-0. Epub 2009 May 7.
The goal of this study was to investigate whether vancomycin (VCM) has a negative effect on pancreatic tissue and to elucidate the role of erdosteine (ERD), an expectorant and an antioxidant agent, on possible VCM-induced pancreas impairment in rats.
A total of 21 male Wistar albino rats were included in this study. All animals were equally divided into three groups as follows: Controls (n = 7), VCM treated group (200 mg/kg twice daily for 7 days intraperitoneally, n = 7) and VCM (200 mg/kg) + ERD treated group (10 mg/kg day orally ERD, n = 7). The first dose of ERD administration was performed 24 h prior to VCM injection and the study was continued for 7 days. At the end of the study, all animals were sacrificed. Blood and pancreas tissue samples were collected. For biochemical analysis, serum amylase, lipase, alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT) activities were measured. For histopathological examination, pancreas tissue samples were investigated under the light microscope.
VCM administration has significantly increased the serum amylase, lipase, ALP, and GGT activities, when compared with the controls. VCM + ERD administration significantly decreased the serum lipase, amylase, and GGT activities. There was no statistically significant difference between the VCM + ERD treated group and only VCM treated group by means of serum ALP levels. It has been observed that there was a prominent pancreatic tissue damage in only VCM given group. However, ERD exhibited structural protection against VCM-induced pancreatic damage and this effect was statistically significant. ERD has also obtained a marked reduction in the extent of pancreatic damage.
Erdosteine may play an important role in the VCM-induced pancreatic damage and may reduce the pancreatic damage both in biochemical and histopathological aspects.
本研究旨在探讨万古霉素(VCM)是否对胰腺组织有不良影响,并阐明黏液溶解剂厄多司坦(ERD)在大鼠可能由 VCM 引起的胰腺损伤中的作用。
本研究共纳入 21 只雄性 Wistar 白化大鼠。所有动物均平均分为三组:对照组(n = 7)、VCM 处理组(200mg/kg,每日两次,腹膜内注射,共 7 天,n = 7)和 VCM(200mg/kg)+ ERD 处理组(10mg/kg,每日口服 ERD,n = 7)。首次给予 ERD 治疗是在 VCM 注射前 24 小时进行的,研究持续 7 天。研究结束时,所有动物均被处死。采集血液和胰腺组织样本。进行生化分析时,测量血清淀粉酶、脂肪酶、碱性磷酸酶(ALP)和γ-谷氨酰转移酶(GGT)的活性。进行组织病理学检查时,在光镜下观察胰腺组织样本。
与对照组相比,VCM 给药显著增加了血清淀粉酶、脂肪酶、ALP 和 GGT 活性。VCM+ERD 给药显著降低了血清脂肪酶、淀粉酶和 GGT 活性。VCM+ERD 治疗组与仅 VCM 处理组的血清 ALP 水平无统计学差异。仅给予 VCM 组观察到胰腺组织明显损伤。然而,ERD 对 VCM 诱导的胰腺损伤表现出明显的结构保护作用,且这种作用具有统计学意义。ERD 还显著降低了胰腺损伤的程度。
厄多司坦可能在 VCM 诱导的胰腺损伤中发挥重要作用,并可能在生化和组织病理学方面减轻胰腺损伤。